Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
about
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceDisordered follicle developmentAnti-Müllerian hormone: ovarian reserve testing and its potential clinical implicationsComparability of antimüllerian hormone levels among commercially available immunoassaysThe impact of depot GnRH agonist on AMH levels in healthy reproductive-aged womenBiologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in womenFSH and its second messenger cAMP stimulate the transcription of human anti-Müllerian hormone in cultured granulosa cells.The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesisMaternal antimullerian hormone levels do not predict fetal aneuploidy.Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization.Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHHRole of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis.Prediction of reproductive outcomes according to different serum anti-Müllerian hormone levels in females undergoing intracystoplasmic sperm injectionThe correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile womenSingle nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti-Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology.Cut-Off Levels of Anti-Mullerian Hormone for The Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome.Effects of GnRH agonists on the expression of developmental follicular anti-mullerian hormone in varying follicular stages in cyclic mice in vivo.Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients.The effect of abdominal radical trachelectomy on ovarian reserve: serial changes in serum anti-müllerian hormone levelsFertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunityGenetics of polycystic ovary syndrome: searching for the way out of the labyrinth.Maternal antimullerian hormone as a predictor of fetal aneuploidy occurring in an early pregnancy loss.Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: effects of recombinant LH administration.Serum anti-Müllerian hormone and inhibin B levels at ovulation triggering day can predict the number of immature oocytes retrieved in in vitro fertilization cycles.Association between serum anti-Müllerian hormone level and ovarian response to mild stimulation in normoovulatory women and anovulatory women with polycystic ovary syndromeThe relationship between Anti-Müllerian hormone and other reproductive parameters in normal women and in women with polycystic ovary syndromeWhy Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late!Anti mullerian hormone: a potential marker for recruited non growing follicle of ovarian pool in women with polycystic ovarian syndrome.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).The effect of ovarian puncture on the endocrine profile of PCOS patients who undergo IVMThe correlation of the antral follicle count and Serum anti-mullerian hormone.Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs.Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction.Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases.Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology.Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes.
P2860
Q26829747-CDFACDE5-D2B4-42DE-A671-A1A43429CBC7Q26851230-090E7BC6-3320-4C79-9D65-81E6B5CF5EDBQ28239980-D708B09E-040F-4D52-B1A4-0F6D2913295FQ28388149-AA5BD81D-D4A0-42DC-A543-F12C9EBC08EEQ28392230-556ABD2B-21EF-4B0B-B334-EF75C1300294Q30439646-43260812-6B3B-4535-9F3D-A91D10485650Q33636964-69745FB7-57DE-46E1-8139-24803C4C3567Q33926671-C7CC0572-281F-4B70-A2EB-2179DBBE4D11Q34070204-83CE7F5B-20DE-4C42-B021-F679E68E0839Q34138075-207A901B-DB53-4512-B4E1-76CDBAECC082Q34226336-E22C7386-6B79-4D1E-8E45-3317714A6408Q34700094-2157D8A1-A30B-4C16-8C60-09C112F0A903Q34999705-5D7D0600-4938-4210-B94F-0A8A43403DCAQ35166382-426DB265-5063-41B7-BC84-D37F5A1EFD45Q35186943-C7CF79B5-814F-4B87-B986-74B07E4D2CE8Q35898934-813EA828-C241-407E-AD57-6E29705DC218Q35919719-2BBA51D0-349C-49F2-8AF3-AB229344E6EEQ35946575-83F1A996-5F73-4B02-B8DA-3DD7B2E1A1BAQ35966464-EEA80FDF-DD8E-4A4B-A906-A3515B0A1716Q35966481-0C82E77A-A515-4325-B070-75952B58E9EFQ35976287-30A469C9-8720-48BA-AEDE-36189B34E0E7Q36082015-06FDC100-43C9-4518-ADCF-988A65E3C6A8Q36182579-82349445-3B76-466A-8C19-FEE7061EE743Q36328655-6A7CDC2F-8EFD-42C5-B5CC-5941502D0CC4Q36483196-53344255-778E-4D4C-A6FF-F67E793D7DD6Q36484614-78F92F4E-3A72-4F8F-83E8-79258CBF973FQ36853993-75AFA68E-FC4A-46E6-9397-55F61ADFDA37Q37022417-5D6EDDBF-B1F2-4DB9-B983-03AC900BA166Q37050664-B9E18969-7814-461C-A680-4E3F70277FDFQ37218794-CE102FCC-BB5D-4A06-8572-018FA703565BQ37258799-D8AB5298-A4AD-4873-8FC1-A8E09EE2AED9Q37606149-F5F84634-7AE3-43AC-B95C-0C9C1D7B0698Q37607260-0E8BAE90-27F6-4124-B95E-C08297A8E3C7Q37611192-4A23D0FB-9BCC-46F4-9F07-6BE694DF8AEFQ37611215-318C9040-0391-4BDB-81E6-03055AEA58E4Q38482450-5EC5B1C9-5151-4E91-AAC2-DC6B05DB32BCQ38938581-B91562CF-AC4C-4046-91F5-9D2A469E88D7Q39888178-3CAA1B4C-BF5B-49BB-8640-B0166A4993DBQ40394248-EFE5A7F1-F099-4DB5-837B-64A1B5171893Q42491370-B8834C49-B35F-4478-BE17-FB8DA827D614
P2860
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@en
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@nl
type
label
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@en
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@nl
prefLabel
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@en
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@nl
P2093
P356
P1433
P1476
Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation.
@en
P2093
Claudia Righini
Joëlle Taieb
Luca Maria Schonäuer
Nelly Frydman
Renato Fanchin
René Frydman
P304
P356
10.1093/HUMREP/DEG043
P407
P577
2003-02-01T00:00:00Z